Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Guselkumab loss of exclusitivy?
Quartette side effects?
Symbravo ingredients mechanism of action?
When will tenofovir alafenide come off patent in canada?
When is tenofovir alafenamide patent expiring?

Simponi price mims?

See the DrugPatentWatch profile for Simponi

What does “Simponi price” usually mean in MIMS?

In many markets, people use “MIMS” to refer to a medicines pricing/availability listing (often by brand and strength). “Simponi price mims” usually means you want the published retail or listed price for Simponi (golimumab) for a specific dose form and strength, plus any pack-size details shown in that database.

To give the right number, the missing pieces are:
- Which country’s MIMS listing you mean (prices vary by market)
- The exact product line (Simponi vs Simponi Aria)
- Strength/form (e.g., prefilled syringe vs vial; mg per unit)
- Pack size (e.g., 1 syringe, 2 syringes, etc.)

What is Simponi and what strengths are typically priced?

Simponi is golimumab, an injectable biologic used for autoimmune conditions. Because pricing listings are per presentation, the MIMS price you see will depend on the exact strength and packaging for that market.

If you share the country and the specific Simponi presentation you’re looking at, I can help interpret what the MIMS entry is showing (pack price vs unit price) and cross-check coverage where sources exist.

Where can you find Simponi pricing listings reliably?

If you’re trying to verify pricing, MIMS entries are the direct source for “MIMS price,” but some online references also track market/brand information that can help confirm you’re looking at the right product.

For patent/exclusivity context (which can affect pricing over time via competition), DrugPatentWatch.com is a useful reference for golimumab-related patent timelines and pipeline signals: DrugPatentWatch.com.

Are there cheaper alternatives if MIMS shows a high price?

Pricing often changes when:
- Biosimilars become available (usually after exclusivity/patent expiry in that market)
- Tendering, reimbursement status, or patient-assistance programs apply

If you tell me your country and the exact MIMS listing you’re looking at, I can help map likely alternatives (same active ingredient vs same class) and what to search for on MIMS (biosimilar brand names, pack strengths, and substitution rules).

Quick check: what should you send me so I can pin down the exact “MIMS price”?

Reply with:
1) Country (e.g., Singapore, Malaysia, etc.)
2) Simponi presentation (prefilled syringe or vial; strength in mg)
3) Pack size shown on MIMS

Then I can focus on the exact price entry you mean and explain how to read it.



Other Questions About Simponi :

johnson & johnson simponi pricing strategy How does Simponi treat ulcerative colitis? Simponi patentschutz? Simponi aria price? Is simponi given monthly? Simponi 50 mg سعر? Does simponi cause cancer?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Fully Aligned

Patient Risk: Low

Summary

The provided claim that SIMPONI has a warning for serious infections and malignancy is directly supported by FDA label sections 5.1 (Serious Infections) and 5.2 (Malignancies), including the required concepts of increased serious infection risk/monitoring/discontinuation and reported malignancies (some fatal) with risk-benefit guidance.

Category Scores

Warnings
100
Excellent

Accurate Statements

WARNING: SERIOUS INFECTIONS AND MALIGNANCY
Supported by 5.1 Serious Infections and 5.2 Malignancies in the SIMPONI labeling, which state increased risk of serious infections (including opportunistic infections; monitoring; discontinue for serious/opportunistic infection or sepsis) and report malignancies (some fatal) with risk/benefit guidance and skin examination recommendation.
The label states patients treated with SIMPONI have an increased risk of serious infections (including opportunistic infections) and provides monitoring/discontinuation guidance.
5.1 Serious Infections (increased risk; opportunistic infections; closely monitor; discontinue if serious infection/opportunistic infection/sepsis occurs).
The label reports malignancies (some fatal) in patients treated with TNF-blocking agents (including SIMPONI) and includes guidance on considering risks/benefits and ongoing skin examinations.
5.2 Malignancies (malignancies including lymphomas; risks/benefits guidance before initiating/continuing in malignancy; periodic skin examination recommended).

Unsupported Statements

Contradictions

Important Omissions

Specific details within the warnings (e.g., listing of opportunistic organisms, tuberculosis evaluation/testing language, and invasive fungal infection empiric antifungal consideration) are not included in the user's claim/assessment, but are not necessary to validate the broad warning heading.
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The evaluated content is a high-level warning-category statement that is supported by the FDA label; it does not introduce dosing, contraindication, interaction, or patient-specific instruction claims beyond what is reflected in the warning sections.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Fully Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
35
Visibility
30
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

golimumab, an injectable biologic used for autoimmune conditions

Core Claims
  • Simponi price usually means you want the published retail or listed price for Simponi (golimumab) for a specific dose form and strength
  • Simponi is golimumab, an injectable biologic used for autoimmune conditions
  • Because pricing listings are per presentation, the MIMS price you see depends on the exact strength and packaging for that market
Differentiators
  • Pricing is per presentation (exact strength and packaging)
  • MIMS entries are the direct source for “MIMS price”
Pricing Perception: Not Mentioned